Treatment is typically started at 1ml/cc per injection once weekly
Although the overall evidence suggests that at least a subset of patients with ME/CFS exhibit reduced cortisol output, some cohorts show only modest reductions, preserved cortisol output, or context-dependent abnormalities rather than stable hypocortisolism, indicating that HPA-axis dysfunction in ME/CFS is likely heterogeneous and multifactorial rather than a specific or uniform neuroendocrine abnormality (Cleare, 2003
Who Can Benefit from the GLOW Peptide Complex
In the battle of concentrated whey vs isolate, we think concentrate wins hands down
doi: 10.1111/j.1469-8749.2009.03606.x
Australian regulations require that peptide products for therapeutic use carry an ARTG (Australian Register of Therapeutic Goods) number, with 78% of verified GHK-Cu products meeting this criterion as of 2024